World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions by Kaptoge, Stephen et al.
www.thelancet.com/lancetgh   Vol 7   October 2019 e1332
Articles
World Health Organization cardiovascular disease risk charts: 
revised models to estimate risk in 21 global regions
The WHO CVD Risk Chart Working Group*
Summary
Background To help adapt cardiovascular disease risk prediction approaches to low-income and middle-income 
countries, WHO has convened an effort to develop, evaluate, and illustrate revised risk models. Here, we report the 
derivation, validation, and illustration of the revised WHO cardiovascular disease risk prediction charts that have 
been adapted to the circumstances of 21 global regions.
Methods In this model revision initiative, we derived 10-year risk prediction models for fatal and non-fatal 
cardiovascular disease (ie, myocardial infarction and stroke) using individual participant data from the Emerging 
Risk Factors Collaboration. Models included information on age, smoking status, systolic blood pressure, history of 
diabetes, and total cholesterol. For derivation, we included participants aged 40–80 years without a known baseline 
history of cardiovascular disease, who were followed up until the first myocardial infarction, fatal coronary heart 
disease, or stroke event. We recalibrated models using age-specific and sex-specific incidences and risk factor values 
available from 21 global regions. For external validation, we analysed individual participant data from studies distinct 
from those used in model derivation. We illustrated models by analysing data on a further 123 743 individuals from 
surveys in 79 countries collected with the WHO STEPwise Approach to Surveillance.
Findings Our risk model derivation involved 376 177 individuals from 85 cohorts, and 19 333 incident cardiovascular 
events recorded during 10 years of follow-up. The derived risk prediction models discriminated well in external 
validation cohorts (19 cohorts, 1 096 061 individuals, 25 950 cardiovascular disease events), with Harrell’s C indices 
ranging from 0·685 (95% CI 0·629–0·741) to 0·833 (0·783–0·882). For a given risk factor profile, we found 
substantial variation across global regions in the estimated 10-year predicted risk. For example, estimated 
cardiovascular disease risk for a 60-year-old male smoker without diabetes and with systolic blood pressure of 
140 mm Hg and total cholesterol of 5 mmol/L ranged from 11% in Andean Latin America to 30% in central Asia. 
When applied to data from 79 countries (mostly low-income and middle-income countries), the proportion of 
individuals aged 40–64 years estimated to be at greater than 20% risk ranged from less than 1% in Uganda to more 
than 16% in Egypt.
Interpretation We have derived, calibrated, and validated new WHO risk prediction models to estimate cardiovascular 
disease risk in 21 Global Burden of Disease regions. The widespread use of these models could enhance the accuracy, 
practicability, and sustainability of efforts to reduce the burden of cardiovascular disease worldwide.
Funding World Health Organization, British Heart Foundation (BHF), BHF Cambridge Centre for Research 
Excellence, UK Medical Research Council, and National Institute for Health Research.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
Introduction
By the year 2030, the UN Sustainable Development Goals1 
aim to reduce premature mortality from non-com-
municable diseases by a third. Cardiovascular diseases 
(which include coronary heart disease and stroke) are 
the most common non-communicable diseases globally, 
respon sible for an estimated 17·8 million deaths in 
2017, of which more than three quarters were in low-
income and middle-income countries.2 To help reduce 
the global burden of cardiovascular disease, WHO 
member states have committed to provide counselling 
and drug treat ments for at least 50% of eligible people 
(defined as aged 40 years or older and at high risk 
of cardio vascular disease) by 2025.3 To support such 
expansion of cardio vascular disease prevention and 
control efforts, WHO has developed tools and guidance, 
including risk prediction charts.4,5
Risk prediction models can be a component of cardio-
vascular disease prevention and control efforts, because 
they can help to identify people at high risk of cardio-
vascular disease who should benefit the most from 
preventive interventions.6,7 Many such risk prediction 
models have been developed,8–13 usually estimating indi-
vidual risk over a 10-year period by use of measured 
levels of conventional risk factors for cardiovascular 
disease.14 However, available models have limitations for 
use in low-income and middle-income countries. Most 
models were derived and validated with use of a narrow 
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set of studies, might be directly applicable only to 
specific populations (mainly in high-income countries), 
and might not predict the correct risk in the target 
population being screened (ie, poor calibration).8,13,15–18
Here, we provide derivation, validation, and 
illustration of updated WHO models for cardiovascular 
disease risk prediction. To enhance targeting of efforts 
to reduce the burden of cardiovascular disease, we have 
statistically adapted (ie, recalibrated)14,19 models to the 
contemporary circumstances of many different global 
regions using routinely available information. The aim 
of recalibration was to ensure that risk prediction 
models estimate risk for individuals in each region 
more accurately. To help make this approach more 
sustainable, we developed and describe here a method 
that can be used to regularly update risk prediction 
models using information about epidemiological trends 
in cardiovascular disease within different global regions. 
The WHO CVD Risk Chart Working Group, a cross-
sectoral collaboration of aca demics, policy makers, and 
end users of risk scores, was convened to facilitate this 
development of revised models for prediction of cardio-
vascular disease risk more tailored to the needs of low-
income and middle-income countries.
Methods
Study design
In our model revision initiative, several interrelated com-
ponents were involved (figure 1). First, we derived 
risk prediction models using individual participant 
data from 85 prospective cohorts in the Emerging 
Risk Factors Collaboration (ERFC). Second, we adjusted 
models to the contemporary circumstances of mul-
tiple global regions, recalibrating models using age-
specific and sex-specific incidences and risk factor values 
obtained from the Global Burden of Disease (GBD) 
studies20,21 and the Non-Communicable Disease Risk 
Factor Collaboration (NCD-RisC).22–24 Third, we completed 
external validation using indi vidual participant data from 
a further 19 prospective cohorts that did not contribute to 
the model derivation. Fourth, models were applied to 
indi vidual participant data from 79 countries collected 
with the WHO STEPwise Approach to Surveillance 
(STEPS).25 Fifth, we used this sequence of analyses to 
assess the potential value of pragmatic risk models (eg, 
those that include information on body-mass index [BMI] 
instead of serum lipid values), because laboratory 
measurements are not widely available in many low-
income and middle-income countries.9,15,26
Data sources and procedures
The ERFC was selected for model derivation because 
it has collated and harmonised individual participant 
data from many long-term prospective cohort studies 
of cardiovascular disease risk factors and outcomes.27,28 
Prospective studies in the ERFC were included in our 
analysis if they met all the following criteria: had recorded 
baseline information on risk factors necessary to derive 
risk prediction models (ie, age, sex, smoking status 
[current vs other], history of diabetes, systolic blood 
Research in context
Evidence before this study
To update the 2007 WHO and International Society of 
Hypertension’s cardiovascular disease risk prediction 
approaches, WHO has convened an informal risk-chart working 
group. To inform this work, we searched PubMed, Scientific 
Citation Index Expanded, and Embase to identify existing risk 
prediction models for cardiovascular disease in the context of 
primary prevention published in any language up to 
May 15, 2019, using the relevant terms: “cardiovascular 
disease”, “risk score”, “risk equation”, “risk algorithm”, and “risk 
prediction”. We found many studies and reviews describing risk 
prediction models to estimate cardiovascular disease risk in a 
primary prevention context. However, none had combined the 
following key features necessary to develop reliable risk models 
relevant to low-income and middle-income countries: use of 
powerful and diverse global data, simple and generalisable 
methods to account for differences in populations (ie, to allow 
recalibration), and inclusion of information that is readily 
available in many low-income and middle-income countries.
Added value of this study
The newly developed risk models involve several features 
that should confer advantages compared with existing tools. 
First, they are underpinned by powerful, extensive, 
and complementary datasets of global relevance. Second, 
we used comprehensive contemporary estimates of 
cardiovascular disease incidence and risk factor values to adapt 
(ie, recalibrate) the risk models to many different populations 
using a simpler and more generalisable approach than that of 
previous studies. Third, these models provide estimates for 
the combined outcome of fatal and non-fatal events. Fourth, 
they include pragmatic models that do not assume availability 
of laboratory measurements (eg, serum lipid concentrations) 
that could be used as part of stepwise approaches to help 
target laboratory testing in people most likely to benefit from 
the extra information.
Implications of all the available evidence
We have derived, validated, and illustrated new WHO models 
for cardiovascular disease risk prediction adapted for the needs 
of low-income and middle-income countries, to support tools 
and guidance for cardiovascular disease prevention and control. 
The widespread use of these models could enhance the 
accuracy, practicability, and sustainability of efforts to reduce 
the burden of cardiovascular disease worldwide.
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pressure, and total cholesterol or BMI), were 
approximately population-based (ie, did not select 
participants on the basis of having previous disease), had 
recorded cause-specific deaths and non-fatal cardio-
vascular disease events (ie, non-fatal myocardial infarc-
tion or stroke) with well defined criteria, and had at least 
1 year of follow-up after baseline (which was deemed to 
be sufficient for estimation of risk factor–disease 
associations in the absence of non-proportional hazards). 
We did not use prospective cohort studies analysed as 
nested case-control studies. Details of the contributing 
studies are described in  appendix 1 (pp 3–5, 37–38).
For the recalibration of models, we obtained age-
specific and sex-specific incidences of myocardial 
infarction and stroke from the 2017 update of the GBD 
study for each of 21 global regions defined by GBD to 
maximise between-region variability and minimise 
heterogeneity within each region in mortality and major 
drivers of health outcomes (appendix 1 p 39).21,29 Age-
specific and sex-specific risk factor values for each of 
these regions were estimated by averaging country-
specific risk factor values provided by the NCD-
RisC.20,22–24,30
We included prospective cohort studies in the external 
validation analysis if they met the following criteria: did 
not contribute to the model derivation stage, met the 
same methodological criteria as those described for the 
cohorts selected from the ERFC for the model derivation 
stage, and made individual participant data accessible 
for analysis to investigators in our working group. 
Studies used for external validation included the 
following: the Asia Pacific Cohort Studies Collaboration 
(APCSC),31 the New Zealand primary care-based 
PREDICT cardio vascular disease cohort (PREDICT-
CVD),12 the Chinese Multi-Provincial Cohort Study,32 the 
Health Checks Ubon Ratchathani Study33 in Thailand, 
the Tehran Lipids and Glucose Study,34 and UK Biobank 
(appendix 1 p 6).35
To mirror the populations typically targeted in primary 
prevention efforts for cardiovascular disease, risk model 
derivation included participants aged 40–80 years 
without a known baseline history of cardiovascular 
disease. Follow-up was until the first myocardial 
infarction, fatal coronary heart disease, or stroke event; 
outcomes were censored if a participant was lost to 
follow-up, died from non-cardiovascular disease causes, 
or reached 10 years of follow-up. Conventional 
cardiovascular disease risk factors were considered for 
selection as variables in risk models if they were known 
to be predictive of cardiovascular disease in different 
populations, were recorded in available survey data to 
allow systematic recalibration within each global 
region,20,22–24,30 and had been shown to be measurable at 
low cost in low-income and middle-income countries.20 
We derived two types of new WHO risk prediction 
models for cardiovascular disease: a laboratory-based 
model including age, smoking status, systolic blood 
pressure, history of diabetes, and total cholesterol; and a 
non-laboratory-based model including age, smoking 
status, systolic blood pressure, and BMI. Sex-specific 
models were derived separately for coronary heart 
disease (defined in the ERFC dataset as non-fatal 
myocardial infarction or fatal coronary heart disease), 
and stroke (any fatal or non-fatal cerebrovascular event) 
outcomes. Details of these endpoint definitions are 
shown in appendix 1 (p 7).  Outcomes were model led 
separately for coronary heart disease and stroke to allow 
separate recalibration to the disease-specific incidence 
in the target populations before combination in a single 
estimation equation for cardiovascular disease risk 
(appendix 1 pp 40–41). The assumption of indepen dence 
between coronary heart disease and stroke risk was 
checked with data from ERFC cohorts (appendix 1 p 15).
Statistical analysis
We estimated hazard ratios (HRs) using Cox 
proportional hazards models, stratified by study and 
with duration (ie, time from entry into the study) as the 
Figure 1: Study design
ERFC=Emerging Risk Factors Collaboration. GBD=Global Burden of Disease. IHME=Institute for Health Metrics 
and Evaluation. NCD-RisC=Non-Communicable Diseases Risk Factor Collaboration. APCSC=Asia Pacific Cohort 
Studies Collaboration. CMCS=Chinese Multi-Provincial Cohort Study. TLGS=Tehran Lipids and Glucose Study. 
PREDICT-CVD=New Zealand primary care-based PREDICT-CVD cohort. HCUR=Health Checks Ubon Ratchathani 
Study in Thailand. WHO STEPS=WHO STEPwise Approach to Surveillance.
Model derivation and internal 
validation
Application to country-specific 
data
ERFC data 
85 cohorts, 376 177 individuals with 19 333 cardiovascular disease events 
within 10 years
Model recalibration to 21 global 
regions
GBD study estimates 
Age-specific and sex-specific annual incidence rates of myocardial 
infarction and stroke estimated by IHME for 21 global regions
NCD-RisC estimates
Country-specific mean risk factor values by age and sex, averaged within 
21 global regions
External cohorts 
(19 cohorts, 1 096 061 individuals, 25 950 events)
APCSC 
14 cohorts, 43  735 individuals, 2219 events
CMCS
17 167 individuals, 1613 events
TLGS
4921 individuals, 400 events
PREDICT-CVD
254 680 individuals, 6857 events
HCUR 
330 985 individuals, 6409 events
UK Biobank
444 573 individuals, 8452 events
External validation
WHO STEPS surveys
Individual participant data from 123 743 individuals sampled in surveys 
representative of national or subnational populations from 79 countries
See Online for appendix 1
For the GBD study see 
http://ghdx.healthdata.org/gbd-
results-tool
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timescale (in subsidiary analyses, models were also 
fitted with age as the timescale). Interactions between 
baseline age and other predictors were included 
because outcome associations commonly vary with 
age.36–38 Continuous variables were centred to aid 
interpretation of regression model estimates and 
facilitate recalibration of the models to new populations, 
with age centred at 60 years (the midpoint of the 
defined 40–80 years age range), total cholesterol at 
6 mmol/L, BMI at 25 kg/m², and systolic blood pressure 
at 120 mm Hg. Deviation from the proportional hazards 
assumption was either minimal or non-existent, 
assessed by fitting models including time-varying 
covariates. Between-study heterogeneity was assessed 
using the I² statistic.39 We used meta-regression to 
assess hetero geneity by geographical region and period 
of cohort enrolment.40
For internal validation, we assessed risk discrimination 
using Harrell’s C index. This index estimates the 
probability of the model correctly predicting who will 
have a cardiovascular disease event first in a randomly 
selected pair of participants.41 To avoid optimism that 
might result from assessing risk discrimination in the 
data from which the model was derived, we used an 
internal–external validation approach in which each 
study was, in turn, left out of the model derivation and 
used to calculate a validation C index.42 The calibration 
of each model within studies with at least 10 years of 
follow-up in the derivation dataset was checked by 
comparing observed and predicted risk across deciles of 
predicted risk and by calculating a χ² statistic to quantify 
any evidence of lack of agreement or fit (appendix 1 
p 40).43
Recalibration was done separately for men and women 
(description in appendix 1 pp 16,40–41).44 This process 
involved the use of age-specific and sex-specific mean risk 
factor levels and annual incidence estimates of fatal or 
non-fatal myocardial infarction and stroke events in 
each of 21 global regions (appendix 1 p 43). Calibration of 
the new WHO models was assessed by comparing the 
predicted 10-year cardiovascular disease risk with the 
expected 10-year risk estimated from the 2017 GBD 
annual incidence estimates, across 5-year age groups. An 
additional external calibration assessment was com-
pleted in the PREDICT-CVD cohort (the only nationally 
representative validation cohort available to us). Because 
fewer than 10 years of follow-up were available in this 
cohort, we recalibrated models to estimate 5-year risk. We 
assessed discrimination using all external validation 
cohorts by calculating study-specific C indices before 
pooling by country, weighting by number of events.45 
Additionally, we compared C indices for the same 
prediction models derived within datasets used for 
external validation with those calculated for the new 
WHO models. To compare the proportion of the 
population at different levels of cardiovascular disease 
risk, with the WHO models, across multiple countries, 
we applied the risk models to WHO STEPS surveys data. 
To allow comparison across countries, we restricted 
analysis to the latest survey year available for each country 
and to individuals aged 40–64 years, with total cholesterol 
between 2·6–10·3 mmol/L, and complete data on 
relevant variables (appendix 1 pp 8–9). These data 
were also used to compare risk estimates obtained with 
non-laboratory-based models with those obtained with 
laboratory-based models.
Our approach to model development and validation 
complies with the guideline for Transparent Reporting 
of a multivariable prediction model for Individual 
Prognosis Or Diagnosis (appendix 1 pp 44–45). Analyses 
were done with Stata, version 14, two-sided p values, 
and 95% CIs. The study was designed and done by the 
WHO CVD Risk Chart Working Group in collaboration 
with the ERFC academic coordinating centre and was 
approved by the Cambridgeshire Ethics Review 
Committee.
Role of the funding source
The academic investigators and representatives of WHO 
participated in the design and oversight of the project. 
The academic investigators at the coordinating centre 
had full access to all the data and had final responsibility 
for the decision to submit for publication. All authors 
gave approval to submit for publication.
Men Women
Study-level characteristics
Number of studies 80 62 
Year of recruitment* 1960–2008 1960–2013
Baseline characteristics
Total participants 202 962 173 215
Age at baseline survey (years) 53 (48–60) 55 (49–63)
Systolic blood pressure (mm Hg) 132 (120–146) 130 (118–145)
Total cholesterol (mmol/L) 5·7 (5·0–6·5) 5·9 (5·2–6·7)
Current smoking status 76 943 (37·9%) 38 170 (22·0%)
History of diabetes 9939 (4·9%) 8008 (4·6%)
BMI (kg/m²)† 25·6 (23·5–28·0) 25·3 (22·8–28·6)
Cardiovascular outcomes‡
Fatal or non-fatal MI or CHD death§ 18 987 7226
Fatal or non-fatal stroke¶ 8870 6682
Follow-up to first cardiovascular disease event 
(years; median [5–95th percentile range])
10·3 (3·4–30·4) 13·1 (4·4–27·0)
Data are n (%) or median (25–75th percentile range), unless otherwise specified. Data are from a total of 85 cohorts 
with 376 177 participants. BMI=body-mass index. MI=myocardial infarction. CHD=coronary heart disease. 
*41 cohorts (including 47% of total participants) had the median year of study baseline before 1990; 44 cohorts 
(including 53% of total participants) had the median year of study baseline of 1990 or after. †Percentage of 
individuals in WHO-defined BMI categories were the following (in kg/m²): 1·3% with BMI lower than 18·5, 
43·2% with BMI 18·5–24·9, 40·5% with BMI 25·0–29·9, 11·6% with BMI 30–34·9, 2·6% with BMI 35·0–40·0, and 
0·8% with BMI higher than 40. ‡Specific International Classification of Diseases codes are given for each endpoint in 
the appendix (p 7). §Number of fatal or non-fatal MI events or CHD deaths occurring during the first 10 years of 
follow-up: 9456 in men and 3151 in women. ¶Number of fatal or non-fatal stroke events during the first 10 years of 
follow-up: 3722 in men and 3004 in women. 
Table 1: Summary of available data from the Emerging Risk Factors Collaboration used in WHO risk 
model derivation
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Results
Our risk model derivation involved 376 177 participants 
without preceding cardiovascular disease, recruited 
between 1960 and 2013 (table 1, appendix 1 pp 3–5,10). 
Mean age was 54 years (SD 9) among men and 56 years 
(9) among women. 247 699 (66%) of 376 177 participants 
were recruited in European countries, 85 098 (23%) in 
North America, and the remainder mostly in Japan and 
Australia. During the initial 10 years of follow-up 
(3·2 million person-years at risk) 19 333 cardiovascular 
disease events were observed (table 1, appendix 1 pp 3–5). 
HRs for myo cardial infarction or fatal coronary heart 
disease and stroke for each risk predictor included in 
the WHO models are provided in table 2. Associations 
of history of diabetes and current smoking status with 
cardiovascular disease diminished with age, particularly 
in women, among whom HRs for myocardial infarction 
or fatal coronary heart disease were reduced from 
4·65 (95% CI 3·46–6·24) for history of diabetes and 
5·58 (4·58–6·81) for smoking status at age 40 years 
to 2·31 (2·04–2·62) for history of diabetes and 2·05 
(1·85–2·29) for smoking status at age 70 years 
(appendix 1 p 17). We found little to moderate 
heterogeneity in HRs across studies and no evidence to 
suggest diff erences in HRs acccording to geographical 
regions or period of cohort enrolment (appendix 1 p 11). 
Calibration and goodness of fit for the prediction models 
were good within the ERFC dataset, both overall 
(appendix 1 p 18) and within specific regions and 
recruitment time periods (appendix 1 p 19). Internally 
validated C indices ranged from 0·666 (95% CI 
0·661–0·672) in men with the non-laboratory-based 
model to 0·757 (0·749–0·765) in women with the 
laboratory-based model (appendix 1 p 12).
According to 2017 GBD estimates, the relative con-
tribution of myocardial infarction and stroke differed 
Men Women
Main effect Age interaction term* Main effect Age interaction term*
Laboratory-based models
Fatal or non-fatal MI or CHD death
Age at baseline per 5 years 1·43 (1·40–1·47) ·· 1·67 (1·60–1·73) ··
Current smoking status 1·76 (1·68–1·84) 0·91 (0·89–0·93) 2·87 (2·64–3·11) 0·85 (0·81–0·88)
Systolic blood pressure per 20 mm Hg 1·30 (1·28–1·33) 0·98 (0·97–0·99) 1·37 (1·33–1·42) 0·99 (0·97–1·00)
History of diabetes 1·90 (1·76–2·04) 0·94 (0·91–0·97) 2·92 (2·60–3·28) 0·89 (0·84–0·94)
Total cholesterol per 1 mmol/L 1·26 (1·24–1·28) 0·98 (0·97–0·99) 1·23 (1·20–1·26) 0·97 (0·96–0·99)
Baseline survival estimate at 10 years† 0·954 ·· 0·989 ··
Fatal or non-fatal stroke
Age at baseline per 5 years 1·64 (1·58–1·70) ·· 1·70 (1·63–1·76) ··
Current smoking status 1·65 (1·53–1·77) 0·93 (0·89–0·96) 2·11 (1·92–2·31) 0·90 (0·86–0·95)
Systolic blood pressure per 20 mm Hg 1·56 (1·51–1·61) 0·96 (0·95–0·97) 1·51 (1·46–1·56) 0·95 (0·94–0·97)
History of diabetes 1·87 (1·67–2·10) 0·88 (0·83–0·93) 2·36 (2·06–2·70) 0·90 (0·84–0·96)
Total cholesterol per 1 mmol/L 1·03 (1·00–1·06) 1·01 (0·99–1·02) 1·03 (0·99–1·06) 0·99 (0·97–1·01)
Baseline survival estimate at 10 years† 0·985 ·· 0·989 ··
Non-laboratory-based models
Fatal or non-fatal MI or CHD death
Age at baseline per 5 years 1·44 (1·41–1·48) ·· 1·69 (1·63–1·76) ··
Current smoking status 1·81 (1·73–1·90) 0·90 (0·88–0·93) 2·98 (2·75–3·24) 0·84 (0·81–0·88)
Systolic blood pressure per 20 mm Hg 1·31 (1·28–1·33) 0·98 (0·97–0·99) 1·40 (1·35–1·44) 0·98 (0·97–1·00)
BMI per 1 kg/m² 1·18 (1·15–1·22) 0·97 (0·96–0·99) 1·14 (1·10–1·18) 0·98 (0·97–1·00)
Baseline survival estimate at 10 years† 0·954 ·· 0·989 ··
Fatal or non-fatal stroke
Age at baseline per 5 years 1·63 (1·57–1·69) ·· 1·69 (1·63–1·75) ··
Current smoking status 1·65 (1·53–1·78) 0·93 (0·89–0·96) 2·10 (1·91–2·30) 0·90 (0·86–0·95)
Systolic blood pressure per 20 mm Hg 1·58 (1·53–1·62) 0·96 (0·94–0·97) 1·54 (1·49–1·60) 0·95 (0·93–0·96)
BMI per kg/m² 1·08 (1·03–1·13) 0·99 (0·97–1·01) 1·02 (0·98–1·06) 1·00 (0·98–1·02)
Baseline survival estimate at 10 years† 0·985 ·· 0·989 ··
Data are HRs (95% CI) from sex-specific Cox-proportional hazards models, stratified by study. Log HRs and heterogeneity statistics are given in appendix 1 (p 11). Age was 
centred at 60 years, systolic blood pressure at 120 mm Hg, total cholesterol at 6 mmol/L, and BMI at 25 kg/m². Smoking status was coded as current versus other, and history 
of diabetes as yes versus no. MI=myocardial infarction. CHD=coronary heart disease. BMI=body-mass index. HR=hazard ratio. *Age at baseline. †Baseline survival for each 
model was estimated by pooling the baseline survival at 10 years across studies with ≥10 years follow-up weighted by number of events by 10 years.
Table 2: Summary of HRs for predictor variables in the WHO risk models derived with use of Emerging Risk Factors Collaboration data
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substantially by region and sex (appendix 1 pp 20–22), 
reinforcing the need for separate recalibration of indi-
vidual models for each endpoint. Myocardial infarction 
incidence was greater for men than for women in all 
regions, but the incidence of stroke was more similar 
between sexes (appendix 1 pp 23–24). The age-specific 
and sex-specific mean risk factor levels used for 
recalibration are presented by region in appendix 1 
Figure 2: Predicted 10-year cardiovascular disease risks for an individual with total cholesterol concentrations of 5 mmol/L and systolic blood pressure of 140 mm Hg, with the WHO 
laboratory-based model, for each region
Countries included in the 21 regions defined by the Global Burden of Disease Study are provided in appendix 1 (p 39). 
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(pp 25–29). The revised WHO charts for cardiovascular 
disease risk estimation in 21 global regions are 
shown in appendix 2 for the laboratory-based and 
non-laboratory-based models. The predicted 10-year 
cardiovascular disease risk estimated with the WHO 
models was within the expected 95% CI ranges, on 
the basis of uncertainty in GBD estimates (appendix 1 
pp 30–31). Additionally, we observed a good agreement 
between 5-year predicted and observed risk in the 
PREDICT-CVD cohort (appendix 1 p 32). The estimated 
absolute risk for a given age and combination of risk 
factors differed substantially across regions (figure 2). 
For example, the estimated 10-year cardiovascular 
disease risk for a 60-year-old male smoker without 
diabetes and with systolic blood pressure of 140 mm Hg 
and total cholesterol of 5 mmol/L ranged from 11% in 
Andean Latin America to 30% in central Asia. Similarly, 
the 10-year risk for a 60-year-old woman with the same 
risk factor profile ranged from 9% in Andean Latin 
America to 23% in eastern Europe, north Africa, and 
the Middle East.
External validation of risk models involved calculation 
of C indices with use of data from 1 096 061 participants 
with no previous cardiovascular disease, recruited into 
19 prospective cohorts (25 950 cardiovascular disease 
events observed; appendix 1 p 6). C indices indicated 
good discrimination, with values for the WHO 
laboratory-based risk model ranging from 0·685 
(95% CI 0·629–0·741) to 0·833 (0·783–0·882; figure 3). 
Furthermore, deriving individual models of myocardial 
infarction or fatal coronary heart disease and stroke 
risk directly in the APCSC gave broadly similar HRs to 
those found in ERFC (appendix 1 p 13); C indices 
obtained with either the WHO or APCSC models were 
almost identical (appendix 1 p 12). When we applied 
recalibrated WHO laboratory-based models to data from 
the 79 countries in the WHO-STEPS surveys (54 of which 
had sufficient data for use with the laboratory-based 
model; appendix 1 pp 8–9), the proportion of individuals 
aged 40–64 years with an estimated risk greater 
than 20% varied by region and country, from less than 
1% for Uganda to greater than 16% for Egypt (figure 4). 
We observed small reductions in the C-index when 
comparing the non-laboratory-based model with the 
laboratory-based risk model (appendix 1 p 33). The risk 
distributions according to the non-laboratory-based 
model are provided in appendix 1 (p 34).
Overall, we found moderate agreement between risk 
predictions based on laboratory and non-laboratory 
models. Of individuals at greater than 20% risk using 
the laboratory-based models, more than 97% of men 
and women were also identified as being at greater 
than 10% risk with the non-laboratory-based models 
(appendix 1 p 35). However, when using a 20% threshold 
with non-laboratory-based models, about 65% of men 
and 35% of women were identified. This discrepancy was 
largely due to poor performance of the non-laboratory 
models in people with diabetes (appendix 1 p 36). For 
example, among individuals with diabetes classified as 
being at greater than 20% risk with the laboratory-based 
models, about 45% of men and 25% of women were 
classified as being at greater than 20% risk with the non-
laboratory-based models (whereas in individuals without 
diabetes, about 85% of men and 95% of women showed 
such agreement; appendix 1 p 36).
Discussion
We have developed, evaluated, and illustrated the use of 
revised prediction models for cardiovascular disease risk 
adapted for low-income and middle-income countries 
(appendix 2), with the aim of their incorporation into the 
WHO HEARTS package.4 These models have been 
system atically recalibrated to contemporary risk factor 
levels and disease incidences across 21 global regions, 
thereby enabling more accurate identification of 
individuals at high risk of cardiovascular disease in 
different settings.46 Because the approach to recalibration 
that we used allows rapid revision of cardiovascular 
disease models, it should enable flexible updating of 
models as relevant new epidemiological data emerge 
about cardiovascular disease trends in particular 
geographical areas.
The risk models described here involve several 
features that should confer advantages compared with 
existing tools.8,9,13,47–49 First, these models are underpinned 
by powerful, extensive, and complementary datasets 
of global relevance, used in a series of interrelated 
analyses for model derivation, recalibration, validation, 
and illus tration of cardiovascular disease risk.20–24 
In parti cular, the scale and geographical resolution of 
the datasets analysed have enhanced the validity and 
generalisability of risk models for each sex-specific and 
disease-specific (myocardial infarction and stroke) 
endpoint reported here.
Figure 3: C index upon assessing ability of the laboratory-based WHO model to discriminate cardiovascular 
disease events in external validation cohorts
Where multiple studies are used, country-specific estimates are the result of pooling study-specific C-index values, 
weighting by the number of events. APCSC=Asia Pacific Cohorts Studies Collaboration. *Calculated with data from 
studies from the APCSC. †Calculated with data from studies from the APCSC and the China Multi-Provincial Cohort 
Study. ‡Calculated with data from the Tehran Lipids and Glucose Study. §Calculated with data from studies from 
the APCSC and the PREDICT-CVD cohort. ¶Calculated with data from the Health Checks Ubon Ratchathani Study. 
||Calculated with data from the UK Biobank.
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Figure 4: Distribution of 
10-year cardiovascular 
disease risk according to 
recalibrated laboratory-based 
WHO risk prediction models 
for individuals aged 
40–64 years from example 
countries
Data from all countries are 
from adults aged 40–64 years 
with total cholesterol 
concentrations of 
2·6–10·3 mmol/L and from 
samples representative of the 
national population, unless 
otherwise specified as 
subnational (S) or community 
based (C). 
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A second feature is the simplicity of the recalibration 
approach we have developed. This approach entails fewer 
modelling steps and avoids reliance on sparse cohort or 
country-level data, providing recalibrated calculators 
tailored to the sex-specific cardiovascular disease rates 
and risk factor levels of each region.48,50,51 Because the 
approach can be used with aggregate (ie, group level) 
data on cardiovascular disease incidences and with 
average risk factor values for any target population to be 
screened, this means that descriptive epidemiological 
data can be readily incorporated to revise models 
according to country-specific cardiovascular disease 
incidence to reflect changes in disease incidences and 
risk factor profiles. To support periodic revisions, we 
have made openly accessible the statistical code needed 
to calculate, validate, and recalibrate these models using 
updated population data.
A third feature is that the risk models reported here 
provide estimates for the combined outcome of fatal and 
non-fatal events, thereby improving on risk calculators 
that predict fatal events alone.8 Although information 
on fatal event rates is often easier to obtain at a 
country-specific level, the use of mortality risk models 
might underestimate total cardiovascular disease risk, 
particularly for individuals in populations where the case-
fatality rate is low (as is typically observed among younger 
individuals).15 Because the models reported here have 
been specifically derived for and recalibrated to the sex-
specific and age-specific rates of myocardial infarction 
and stroke in each region, they should avoid inaccuracies 
that could arise from recalibration to overall cardiovascular 
disease rates,48 including inconsistencies in reporting 
softer endpoints (such as angina) across regions.
A fourth feature is the assessment of pragmatic models 
that do not assume availability of laboratory measure-
ments (eg, serum lipid concentrations). Such simplified 
approaches could be used in resource-constrained 
settings as part of stepwise approaches to help target 
laboratory testing in people most likely to benefit from 
the extra information (eg, pre-selection tools),26 and used 
even when values for some risk factors are unavailable for 
individuals (when mean values from the relevant 
population can be used as crude surrogates).13 However, 
we found that an important limitation of such pragmatic 
scores was their poor performance among people with 
diabetes.
A fifth feature was that, because we could illustrate the 
performance of the new models with reference to 
surveillance data from 79 countries, our data have shown 
that the proportion of individuals across different risk 
categories is strikingly different across global regions. 
This finding suggests that our risk estimates should 
assist policy makers to make more appropriate and 
locally informed decisions about the allocation of 
prevention resources. 
Finally, we have presented revised risk charts in an 
analogous manner to previous WHO–International 
Society of Hypertension (ISH) versions to help facilitate 
continuity of use. Nevertheless, the colour code has 
been revised to reflect the general lower estimated 
absolute risk levels compared with those of previous 
WHO–ISH models.47 Orange sections now indicate 
10-year risk greater than 10%, whereas red sections 
indicate a risk greater than 20% (as opposed to 
>20% indicated in orange and >30% indicated in red 
previously).
The potential limitations of our study merit con-
sideration. We derived risk prediction models from 
85 cohorts mostly from high-income countries in the 
ERFC. Ideally, however, the derivation of risk models for 
low-income and middle-income countries would involve 
nationally representative, large-scale prospective cohort 
data from several of these countries, each cohort with 
long-term follow-up and validated fatal and non-fatal 
endpoints. Unfortunately, however, such data do not 
yet exist for most low-income and middle-income 
countries.21,29,52 Therefore, to inform recalibration, we 
used data from the GBD study and the NCD-RisC, 
acknowledging that these sources frequently do not have 
country-specific disease risk estimates because of the 
paucity or absence of such data.21,29,52
To provide external validation, we analysed data from 
19 cohorts distinct from those used in model derivation. 
However, only one of them (PREDICT-CVD cohort) 
was nationally representative, whereas some of the 
other cohorts might have inadequately represented the 
epidemiology of cardiovascular disease in contemporary 
national populations of interest.44 Our risk models 
might have overestimated cardiovascular disease risk 
for primary prevention purposes because incidences 
from global regions used to recalibrate models were 
likely to include some recurrent events (although the 
extent of such overestimation is difficult to quantify).53 
Conversely, our risk models might have underestimated 
cardio vascular disease risk because population data 
used to estimate incidences were likely to include some 
people already on cardiovascular disease prevention 
therapies (eg, statins or anti-hypertensive medication). 
However, data available to us were insufficient to 
explore this issue in detail. We could not compare the 
performance of our new risk models with risk equations 
already developed for use in specific high-income 
countries or regions because these equations typically 
contain some variables that are not available (or cannot 
be practicably measured) in low-income and middle-
income countries.6,8,12,13,16,54 Models were derived on 
participants with complete risk factor information, 
which, in principle, could cause a loss in efficiency 
and bias results. However, our analyses were well 
powered and should be unbiased under the reasonable 
assumption that the probability of an individual having 
complete risk factor information is independent of 
cardiovascular disease, given the variables included in 
the prediction model.55
For the statistical code see 
http://www.phpc.cam.ac.uk/ceu/
erfc/programs/
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In conclusion, we have derived, validated, and illus-
trated new WHO risk prediction models to estimate 
cardio vascular disease risk in 21 GBD regions. Because 
the risk prediction models reported here have been 
adapted to the contemporary circumstances of many 
different global regions and can be readily updated 
with routinely avail able information, their widespread 
use could enhance the accuracy, practicability, and 
sustainability of efforts to reduce the burden of 
cardiovascular disease worldwide.
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Prospective Study of Pravastatin in the Elderly at Risk: Stella Trompet, 
David J Stott; Quebec Cardiovascular Study: Jean-Pierre Després, 
Benoît Lamarche, Bernard Cantin; Rancho Bernardo Study: 
Gail A Laughlin, Lori B Daniels, Linda K McEvoy; Reykjavik Study: 
Thor Aspelund, Bolli Thorsson, Elias Freyr Gudmundsson; The 
Rotterdam Study: Banafsheh Arshi, Elif Aribas, Oscar L Rueda-Ochoa, 
M Kamran Ikram, Alis Heshmatollah, M Arfan Ikram; Scottish Heart 
Health Extended Cohort: Mark Woodward; Study of Health in 
Pomerania: Marcus Dörr, Matthias Nauck; Strong Heart Study: 
Barbara Howard, Ying Zhang, Stacey Jolly; Speedwell Study: 
Yoav Ben-Shlomo; Turkish Adult Risk Factor Study: Günay Can, 
Hüsniye Yüksel; Toyama Study: Hideaki Nakagawa, Yuko Morikawa, 
Masao Ishizaki; Tromsø Study: Tom Wilsgaard, Ellisiv Mathiesen; 
Uppsala Longitudinal Study of Adult Men: Vilmantas Giedraitis, 
Martin Ingelsson; US Physicians Health Study 2: Nancy Cook, 
Julie Buring; Prospect EPIC (UTRECHT): Yvonne T van der Schouw; 
Württemberg Construction Worker Cohort: Heiner Claessen, 
Dietrich Rothenbacher, Volker Arndt; Whitehall II Study: 
Martin Shipley; Women’s Health Study: Nancy Cook, Julie Buring; 
West of Scotland Coronary Prevention Study: Chris Packard, 
Michele Robertson, Robin Young; Zaragoza Study: 
Alejandro Marín Ibañez; Zutphen Elderly Study: Edith Feskens, 
Johanna M Geleijnse.
Investigators of the Asia Pacific Cohort Studies Collaboration (APCSC)
APCSC Executive Committee: X Fang, D F Gu, R Huxley, Y Imai, 
H C Kim, T H Lam, W H Pan, A Rodgers, I Suh, H Ueshima, 
M Woodward. Aito Town: A Okayama, H Ueshima; H Maegawa; 
Akabane: M Nakamura, N Aoki; Anzhen02: Z S Wu; Anzhen: C H Yao, 
Z S Wu; Australian Longitudinal Study of Aging: Mary Luszcz; 
Australian National Heart Foundation: T A Welborn; Beijing Aging: 
Z Tang; Beijing Steelworkers: L S Liu, J X Xie; Blood Donors’ Health: 
R Norton, S Ameratunga, S MacMahon, G Whitlock; Busselton: 
M W Knuiman; Canberra-Queanbeyan: H Christensen; Capital Iron 
and Steel Company: X G Wu; CISCH: J Zhou, X H Yu; Civil Service 
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Workers: A Tamakoshi; CVDFACTS: W H Pan; East Beijing: Z L Wu, 
L Q Chen, G L Shan; Electricity Generating Authority of Thailand: 
P Sritara; Fangshan: D F Gu, X F Duan; Fletcher Challenge: 
S MacMahon, R Norton, G Whitlock, R Jackson; Guangzhou: Y H Li; 
Guangzhou Occupational: T H Lam, C Q Jiang; Hisayama: 
T Ninomiya, J Hata, Y Hirakawa; Hong Kong: J Woo, S C Ho; 
Huashan: Z Hong, M S Huang, B Zhou; Kinmen: J L Fuh; Konan: 
H Ueshima, Y Kita, S R Choudhury; KMIC: I Suh, S H Jee, I S Kim; 
Melbourne: G G Giles; Miyama: T Hashimoto, K Sakata; Newcastle: 
A Dobson; Ohasama: Y Imai, T Ohkubo, A Hozawa; Perth: 
K Jamrozik, M W Knuiman, M Hobbs, R Broadhurst; Saitama: 
K Nakachi; Seven Cities: X H Fang, S C Li, Q D Yang; Shanghai 
Factory Workers: Z M Chen; Shibata: H Tanaka; Shigaraki Town: 
Y Kita, A Nozaki, H Ueshima; Shirakawa: H Horibe, Y Matsutani, 
M Kagaya; Singapore Heart: K Hughes, J Lee; Singapore NHS92: 
D Heng, S K Chew; Six Cohorts: B F Zhou, H Y Zhang; 
Tanno/Soubetsu: K Shimamoto, S Saitoh; Tianjin: Z Z Li, H Y Zhang; 
Western Australia AAA Screenees: P Norman, K Jamrozik; Xi’an: 
Y He, T H Lam; Yunnan: S X Yao.
Investigators of additional studies used in external validation
Chinese Multi-Provincial Cohort Study: Miao Wang, Jing Liu, 
Xingguang Zhang; Health Checks Ubon Ratchathani Study: 
Weera Mahavanakul, Benjawan Wettana, Prasit Boonkert; 
PREDICT-CVD: Katrina Poppe; Tehran Lipids and Glucose Study: 
Fereidoun Azizi, Azita Zadehvakili, Farzad Hadaegh.
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